From Allstar to Insuman, Sanofi Expands ‘Make In India’ Plans
This article was originally published in PharmAsia News
The French drug firm Sanofi is bullish on producing some of its products in India. It first acquired Shantha Biotechnics and it manufacturing capabilities in 2009 and later started making its pen devices locally, and is now setting up a large project to make the human insulin product Insuman.
You may also be interested in...
MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.